nach oben

Clinical Autonomic Research

Erschienen in:

01.02.2015 | Review Article

Multiple system atrophy: the application of genetics in understanding etiology

verfasst von: Monica Federoff, Lucia V. Schottlaender, Henry Houlden, Andrew Singleton

Erschienen in: Clinical Autonomic Research | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Classically defined phenotypically by a triad of cerebellar ataxia, parkinsonism, and autonomic dysfunction in conjunction with pyramidal signs, multiple system atrophy (MSA) is a rare and progressive neurodegenerative disease affecting an estimated 3–4 per every 100,000 individuals among adults 50–99 years of age. With a pathological hallmark of alpha-synuclein-immunoreactive glial cytoplasmic inclusions (GCIs; Papp–Lantos inclusions), MSA patients exhibit marked neurodegenerative changes in the striatonigral and/or olivopontocerebellar structures of the brain. As a member of the alpha-synucleinopathy family, which is defined by its well-demarcated alpha-synuclein-immunoreactive inclusions and aggregation, MSA’s clinical presentation exhibits several overlapping features with other members including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Given the extensive fund of knowledge regarding the genetic etiology of PD revealed within the past several years, a genetic investigation of MSA is warranted. While a current genome-wide association study is underway for MSA to further clarify the role of associated genetic loci and single-nucleotide polymorphisms, several cases have presented solid preliminary evidence of a genetic etiology. Naturally, genes and variants manifesting known associations with PD (and other phenotypically similar neurodegenerative disorders), including SNCA and MAPT, have been comprehensively investigated in MSA patient cohorts. More recently variants in COQ2 have been linked to MSA in the Japanese population although this finding awaits replication. Nonetheless, significant positive associations with subsequent independent replication studies have been scarce. With very limited information regarding genetic mutations or alterations in gene dosage as a cause of MSA, the search for novel risk genes, which may be in the form of common variants or rare variants, is the logical nexus for MSA research. We believe that the application of next generation genetic methods to MSA will provide valuable insight into the underlying causes of this disease, and will be central to the identification of etiologic-based therapies.

Nur mit Berechtigung zugänglich

Ahmed Z, Asi YT, Sailer A et al (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38:4–24. doi:10.1111/j.1365-2990.2011.01234.x PubMed

Stefanova N, Bücke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178. doi:10.1016/S1474-4422(09)70288-1 PubMed

Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284–1288PubMed

Wüllner U, Abele M, Schmitz-Huebsch T et al (2004) Probable multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 75:924–925PubMedCentralPubMed

Osaki Y, Wenning GK, Daniel SE et al (2002) Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology 59:1486–1491PubMed

Scholz SW, Houlden H, Schulte C et al (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65:610–614. doi:10.1002/ana.21685 PubMedCentralPubMed

Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676. doi:10.1212/01.wnl.0000324625.00404.15 PubMedCentralPubMed

Hara K, Momose Y, Tokiguchi S et al (2007) Multiplex families with multiple system atrophy. Arch Neurol 64:545–551. doi:10.1001/archneur.64.4.545 PubMed

Kiely AP, Asi YT, Kara E et al (2013) α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? Acta Neuropathol (Berl) 125:753–769. doi:10.1007/s00401-013-1096-7

10.

Yoshida M (2011) Multiple system atrophy—synuclein and neuronal degeneration. Rinshō Shinkeigaku Clin Neurol 51:838–842

11.

Ozawa T, Tada M, Kakita A et al (2010) The phenotype spectrum of Japanese multiple system atrophy. J Neurol Neurosurg Psychiatry 81:1253–1255. doi:10.1136/jnnp.2009.182576 PubMed

12.

Wenning GK, Wagner S, Daniel S, Quinn NP (1993) Multiple system atrophy: sporadic or familial? Lancet 342:681

13.

Vanacore N (2005) Epidemiological evidence on multiple system atrophy. J Neural Transm 112:1605–1612. doi:10.1007/s00702-005-0380-7 PubMed

14.

Fogel BL, Clark MC, Geschwind DH (2014) The neurogenetics of atypical parkinsonian disorders. Semin Neurol 34:217–224. doi:10.1055/s-0034-1381738 PubMed

15.

Stamelou M, Quinn NP, Bhatia KP (2013) “Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy—a diagnostic guide. Mov Disord Off J Mov Disord Soc. doi:10.1002/mds.25509

16.

Wenning GK, Geser F, Krismer F et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12:264–274. doi:10.1016/S1474-4422(12)70327-7 PubMedCentralPubMed

17.

Gilman S, Sima AA, Junck L et al (1996) Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. Ann Neurol 39:241–255. doi:10.1002/ana.410390214 PubMed

18.

Nirenberg MJ, Libien J, Vonsattel J-P, Fahn S (2007) Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. Mov Disord Off J Mov Disord Soc 22:251–254. doi:10.1002/mds.21231

19.

Huang Y, Hayes M, Harding AJ et al (2006) Anticipation of onset age in familial Parkinson’s disease without SCA gene mutations. Parkinsonism Relat Disord 12:309–313. doi:10.1016/j.parkreldis.2006.01.002 PubMed

20.

Schöls L, Bauer P, Schmidt T et al (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3:291–304. doi:10.1016/S1474-4422(04)00737-9 PubMed

21.

Khan NL, Giunti P, Sweeney MG et al (2005) Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord Off J Mov Disord Soc 20:1115–1119. doi:10.1002/mds.20564

22.

Kim J-Y, Kim SY, Kim J-M et al (2009) Spinocerebellar ataxia type 17 mutation as a causative and susceptibility gene in parkinsonism. Neurology 72:1385–1389. doi:10.1212/WNL.0b013e3181a18876 PubMed

23.

Abele M, Bürk K, Schöls L et al (2002) The aetiology of sporadic adult-onset ataxia. Brain J Neurol 125:961–968

24.

Lin I-S, Wu R-M, Lee-Chen G-J et al (2007) The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord 13:246–249. doi:10.1016/j.parkreldis.2006.04.009 PubMed

25.

Kim H-J, Jeon BS, Shin J et al (2014) Should genetic testing for SCAs be included in the diagnostic workup for MSA? Neurology 83:1733–1738. doi:10.1212/WNL.0000000000000965 PubMed

26.

Stemberger S, Scholz SW, Singleton AB, Wenning GK (2011) Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiol Aging 32(1924):e5–e14. doi:10.1016/j.neurobiolaging.2011.04.001 PubMed

27.

Stemberger S, Wenning GK (2011) Modelling progressive autonomic failure in MSA: where are we now? J Neural Transm 118:841–847. doi:10.1007/s00702-010-0576-3 PubMed

28.

Fernagut P-O, Tison F (2012) Animal models of multiple system atrophy. Neuroscience 211:77–82. doi:10.1016/j.neuroscience.2011.09.044 PubMed

29.

Flabeau O, Meissner WG, Tison F (2010) Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord 3:249–263. doi:10.1177/1756285610375328 PubMedCentralPubMed

30.

Wenning GK, Ben-Shlomo Y, Hughes A et al (2000) What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson’s disease? J Neurol Neurosurg Psychiatry 68:434–440PubMedCentralPubMed

31.

Ozawa T, Paviour D, Quinn NP et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain J Neurol 127:2657–2671. doi:10.1093/brain/awh303

32.

Kisos H, Pukaß K, Ben-Hur T et al (2012) Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies. PLoS One 7:e46817. doi:10.1371/journal.pone.0046817 PubMedCentralPubMed

33.

Rockenstein E, Ubhi K, Inglis C et al (2012) Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy. Neuroreport 23:259–264. doi:10.1097/WNR.0b013e3283509842 PubMedCentralPubMed

34.

Yoshida M (2007) Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathol Off J Jpn Soc Neuropathol 27:484–493

35.

Kato S, Shinozawa T, Takikawa M et al (2000) Midkine, a new neurotrophic factor, is present in glial cytoplasmic inclusions of multiple system atrophy brains. Acta Neuropathol (Berl) 100:481–489

36.

Muramatsu T (1992) Retinoic acid regulates the expression of a new heparin binding growth differentiation factor. J Nutr Sci Vitaminol (Tokyo) Spec No:485–487

37.

Nurcombe V, Fraser N, Herlaar E, Heath JK (1992) MK: a pluripotential embryonic stem-cell-derived neuroregulatory factor. Dev Camb Engl 116:1175–1183

38.

Satoh J, Muramatsu H, Moretto G et al (1993) Midkine that promotes survival of fetal human neurons is produced by fetal human astrocytes in culture. Brain Res Dev Brain Res 75:201–205PubMed

39.

Ishizawa K, Komori T, Sasaki S et al (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43–52PubMed

40.

Lehotzky A, Lau P, Tokési N et al (2010) Tubulin polymerization-promoting protein (TPPP/p25) is critical for oligodendrocyte differentiation. Glia 58:157–168. doi:10.1002/glia.20909 PubMedCentralPubMed

41.

Hasegawa T, Baba T, Kobayashi M et al (2010) Role of TPPP/p25 on α-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int 57:857–866. doi:10.1016/j.neuint.2010.09.002 PubMed

42.

Song YJC, Lundvig DMS, Huang Y et al (2007) p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171:1291–1303. doi:10.2353/ajpath.2007.070201 PubMedCentralPubMed

43.

Sugeno N, Takeda A, Hasegawa T et al (2008) Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 283:23179–23188. doi:10.1074/jbc.M802223200 PubMed

44.

Riedel M, Goldbaum O, Wille M, Richter-Landsberg C (2011) Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of α-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress. J Mol Neurosci MN 43:290–302. doi:10.1007/s12031-010-9439-5

45.

Outeiro TF, Kontopoulos E, Altmann SM et al (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science 317:516–519. doi:10.1126/science.1143780 PubMed

46.

Ozawa T, Revesz T, Paviour D et al (2012) Difference in MSA phenotype distribution between populations: genetics or environment? J Park Dis 2:7–18. doi:10.3233/JPD-2012-11056

47.

Nee LE, Gomez MR, Dambrosia J et al (1991) Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res Off J Clin Auton Res Soc 1:9–13

48.

Vanacore N, Bonifati V, Fabbrini G et al (2005) Case-control study of multiple system atrophy. Mov Disord Off J Mov Disord Soc 20:158–163. doi:10.1002/mds.20303

49.

Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443–9449PubMed

50.

Lee PH, Lim TS, Shin H-W et al (2009) Serum cholesterol levels and the risk of multiple system atrophy: a case-control study. Mov Disord Off J Mov Disord Soc 24:752–758. doi:10.1002/mds.22459

51.

Armstrong RA, Cairns NJ, Lantos PL (2006) Multiple system atrophy (MSA): topographic distribution of the alpha-synuclein-associated pathological changes. Parkinsonism Relat Disord 12:356–362. doi:10.1016/j.parkreldis.2006.02.005 PubMed

52.

Vidal J-S, Vidailhet M, Derkinderen P et al (2010) Familial aggregation in atypical Parkinson’s disease: a case control study in multiple system atrophy and progressive supranuclear palsy. J Neurol 257:1388–1393. doi:10.1007/s00415-010-5638-9 PubMed

53.

Multiple-System Atrophy Research Collaboration (2013) Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 369:233–244. doi:10.1056/NEJMoa1212115

54.

Jeon BS, Farrer MJ, Bortnick SF, Korean Canadian Alliance on Parkinson’s Disease and Related Disorders (2014) Mutant COQ2 in multiple-system atrophy. N Engl J Med 371:80. doi:10.1056/NEJMc1311763#SA1 PubMed

55.

Sharma M, Wenning G, Krüger R, European Multiple-System Atrophy Study Group (EMSA-SG) (2014) Mutant COQ2 in multiple-system atrophy. N Engl J Med 371:80–81. doi:10.1056/NEJMc1311763#SA2 PubMed

56.

Schottlaender LV, Houlden H, Multiple-System Atrophy (MSA) Brain Bank Collaboration (2014) Mutant COQ2 in multiple-system atrophy. N Engl J Med 371:81. doi:10.1056/NEJMc1311763#SA3 PubMed

57.

Bleasel JM, Wong JH, Halliday GM, Kim WS (2014) Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol Commun 2:15. doi:10.1186/2051-5960-2-15 PubMedCentralPubMed

58.

Soma H, Yabe I, Takei A et al (2008) Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes. Mov Disord Off J Mov Disord Soc 23:1161–1167. doi:10.1002/mds.22046

59.

Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease—a double-edged sword. Neuron 35:419–432PubMed

60.

Combarros O, Infante J, Llorca J, Berciano J (2003) Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord Off J Mov Disord Soc 18:1385–1386. doi:10.1002/mds.10540

61.

Nishimura M, Kawakami H, Komure O et al (2002) Contribution of the interleukin-1beta gene polymorphism in multiple system atrophy. Mov Disord Off J Mov Disord Soc 17:808–811. doi:10.1002/mds.10124

62.

Infante J, Llorca J, Berciano J, Combarros O (2005) Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 228:11–13. doi:10.1016/j.jns.2004.09.023 PubMed

63.

Furiya Y, Hirano M, Kurumatani N et al (2005) Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 138:178–181. doi:10.1016/j.molbrainres.2005.04.011 PubMed

64.

Nishimura M, Kuno S, Kaji R, Kawakami H (2005) Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy. Neurosci Lett 374:218–221. doi:10.1016/j.neulet.2004.10.056 PubMed

65.

Shibao C, Garland EM, Gamboa A et al (2008) PRNP M129 V homozygosity in multiple system atrophy vs. Parkinson’s disease. Clin Auton Res Off J Clin Auton Res Soc 18:13–19. doi:10.1007/s10286-007-0447-7

66.

Haïk S, Privat N, Adjou KT et al (2002) Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol (Berl) 103:516–520. doi:10.1007/s00401-001-0499-z

67.

Jendroska K, Hoffmann O, Schelosky L et al (1994) Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson’s syndrome. J Neurol Neurosurg Psychiatry 57:1249–1251PubMedCentralPubMed

68.

Singleton AB, Farrer M, Johnson J et al (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841. doi:10.1126/science.1090278 PubMed

69.

Farrer M, Kachergus J, Forno L et al (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55:174–179. doi:10.1002/ana.10846 PubMed

70.

Hernandez D, Paisan Ruiz C, Crawley A et al (2005) The dardarin G 2019 S mutation is a common cause of Parkinson’s disease but not other neurodegenerative diseases. Neurosci Lett 389:137–139. doi:10.1016/j.neulet.2005.07.044 PubMed

71.

Lincoln SJ, Ross OA, Milkovic NM et al (2007) Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. Parkinsonism Relat Disord 13:340–342. doi:10.1016/j.parkreldis.2006.12.005 PubMedCentralPubMed

72.

Morris HR, Vaughan JR, Datta SR et al (2000) Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. Neurology 55:1918–1920PubMed

73.

Ozawa T, Takano H, Onodera O et al (1999) No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett 270:110–112PubMed

74.

Ozawa T, Healy DG, Abou-Sleiman PM et al (2006) The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry 77:464–467. doi:10.1136/jnnp.2005.073528 PubMedCentralPubMed

75.

Ozawa T, Okuizumi K, Ikeuchi T et al (2001) Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol (Berl) 102:188–190

76.

Vogt IR, Lees AJ, Evert BO et al (2006) Transcriptional changes in multiple system atrophy and Parkinson’s disease putamen. Exp Neurol 199:465–478. doi:10.1016/j.expneurol.2006.01.008 PubMed

77.

Langerveld AJ, Mihalko D, DeLong C et al (2007) Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov Disord Off J Mov Disord Soc 22:766–777. doi:10.1002/mds.21259

78.

Ross OA, Vilariño-Güell C, Wszolek ZK et al (2010) Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol 67:414–415. doi:10.1002/ana.21786 PubMed

79.

Al-Chalabi A, Dürr A, Wood NW et al (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 4:e7114. doi:10.1371/journal.pone.0007114 PubMedCentralPubMed

80.

Simón-Sánchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41:1308–1312. doi:10.1038/ng.487 PubMedCentralPubMed

81.

Satake W, Nakabayashi Y, Mizuta I et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41:1303–1307. doi:10.1038/ng.485 PubMed

82.

Yun JY, Lee W-W, Lee J-Y et al (2010) SNCA variants and multiple system atrophy. Ann Neurol 67:554–555. doi:10.1002/ana.21889 PubMed

83.

Guo XY, Chen YP, Song W et al (2014) SNCA variants rs2736990 and rs356220 as risk factors for Parkinson’s disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.07.014

84.

Gan-Or Z, Bar-Shira A, Dahary D et al (2012) Association of sequence alterations in the putative promoter of RAB7L1 with a reduced parkinson disease risk. Arch Neurol 69:105–110. doi:10.1001/archneurol.2011.924 PubMed

85.

Guo X-Y, Chen Y-P, Song W et al (2014) An association analysis of the rs1572931 polymorphism of the RAB7L1 gene in Parkinson’s disease, amyotrophic lateral sclerosis and multiple system atrophy in China. Eur J Neurol Off J Eur Fed Neurol Soc 21:1337–1343. doi:10.1111/ene.12490

86.

Vilariño-Güell C, Soto-Ortolaza AI, Rajput A et al (2011) MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 76:670–672. doi:10.1212/WNL.0b013e31820c30c1 PubMedCentralPubMed

87.

Wider C, Vilariño-Güell C, Jasinska-Myga B et al (2010) Association of the MAPT locus with Parkinson’s disease. Eur J Neurol Off J Eur Fed Neurol Soc 17:483–486. doi:10.1111/j.1468-1331.2009.02847.x

88.

Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661. doi:10.1056/NEJMoa0901281 PubMedCentralPubMed

89.

Srulijes K, Hauser A-K, Guella I et al (2013) No association of GBA mutations and multiple system atrophy. Eur J Neurol Off J Eur Fed Neurol Soc 20:e61–e62. doi:10.1111/ene.12086

90.

Segarane B, Li A, Paudel R et al (2009) Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 72:1185–1186. doi:10.1212/01.wnl.0000345356.40399.eb PubMedCentralPubMed

91.

Ozelius LJ, Foroud T, May S et al (2007) G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord Off J Mov Disord Soc 22:546–549. doi:10.1002/mds.21343

92.

Tan EK, Skipper L, Chua E et al (2006) Analysis of 14 LRRK2 mutations in Parkinson’s plus syndromes and late-onset Parkinson’s disease. Mov Disord Off J Mov Disord Soc 21:997–1001. doi:10.1002/mds.20875

93.

Heckman MG, Schottlaender L, Soto-Ortolaza AI et al (2014) LRRK2 exonic variants and risk of multiple system atrophy. Neurology 83:2256–2261. doi:10.1212/WNL.0000000000001078 PubMed

94.

Hatano T, Kubo S, Sato S, Hattori N (2009) Pathogenesis of familial Parkinson’s disease: new insights based on monogenic forms of Parkinson’s disease. J Neurochem 111:1075–1093. doi:10.1111/j.1471-4159.2009.06403.x PubMed

95.

Brooks JA, Houlden H, Melchers A et al (2011) Mutational analysis of parkin and PINK1 in multiple system atrophy. Neurobiol Aging 32(548):e5–e7. doi:10.1016/j.neurobiolaging.2009.11.020 PubMed

96.

Buervenich S, Sydow O, Carmine A et al (2000) Alcohol dehydrogenase alleles in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 15:813–818

97.

Buervenich S, Carmine A, Galter D et al (2005) A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample. Arch Neurol 62:74–78. doi:10.1001/archneur.62.1.74 PubMed

98.

Healy DG, Abou-Sleiman PM, Wood NW (2004) Genetic causes of Parkinson’s disease: UCHL-1. Cell Tissue Res 318:189–194. doi:10.1007/s00441-004-0917-3 PubMed

99.

Kim HS, Lee MS (2003) Frequencies of single nucleotide polymorphism in alcohol dehydrogenase7 gene in patients with multiple system atrophy and controls. Mov Disord Off J Mov Disord Soc 18:1065–1067. doi:10.1002/mds.10500

100.

Healy DG, Abou-Sleiman PM, Quinn N et al (2005) UCHL-1 gene in multiple system atrophy: a haplotype tagging approach. Mov Disord Off J Mov Disord Soc 20:1338–1343. doi:10.1002/mds.20575

101.

Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. doi:10.1016/j.neuron.2011.09.010 PubMedCentralPubMed

102.

Goldman JS, Quinzii C, Dunning-Broadbent J et al (2014) Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 71:771–774. doi:10.1001/jamaneurol.2013.5762 PubMedCentralPubMed

103.

Schottlaender LV, Holton JL, Houlden H (2014) Multiple system atrophy and repeat expansions in c9orf72. JAMA Neurol 71:1190–1191. doi:10.1001/jamaneurol.2014.1808 PubMed

104.

Scholz SW, Majounie E, Revesz T et al (2014) Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.08.033

105.

Schottlaender L, Polke JM, Ling H et al (2014) The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.08.024 PubMed

106.

Chu K, Cho J-W, Song E-C, Jeon BS (2002) A patient with proximal myotonic myopathy and parkinsonism. Can J Neurol Sci J Can Sci Neurol 29:188–190

107.

Celik Y, Turgut N, Balci K, Kabayel L (2006) Proximal myotonic dystrophy associated with parkinsonism. J Clin Neurosci Off J Neurosurg Soc Australas 13:275–276. doi:10.1016/j.jocn.2005.01.013

108.

Annic A, Devos D, Destée A et al (2008) Early dopasensitive Parkinsonism related to myotonic dystrophy type 2. Mov Disord Off J Mov Disord Soc 23:2100–2101. doi:10.1002/mds.22239

109.

Sansone V, Meola G, Perani D et al (2006) Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism. J Neurol Neurosurg Psychiatry 77:425–426. doi:10.1136/jnnp.2005.078451 PubMedCentralPubMed

110.

Lim S-Y, Wadia P, Wenning GK, Lang AE (2009) Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. Mov Disord Off J Mov Disord Soc 24:1407–1409. doi:10.1002/mds.22625

111.

Cho S, Kim C-H, Cubells JF et al (2003) Variations in the dopamine beta-hydroxylase gene are not associated with the autonomic disorders, pure autonomic failure, or multiple system atrophy. Am J Med Genet A 120A:234–236. doi:10.1002/ajmg.a.20194 PubMed

112.

Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB (2012) A large study reveals no association between APOE and Parkinson’s disease. Neurobiol Dis 46:389–392. doi:10.1016/j.nbd.2012.02.002 PubMedCentralPubMed

113.

Cairns NJ, Atkinson PF, Kovács T et al (1997) Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neurosci Lett 221:161–164PubMed

114.

Multhammer M, Michels A, Zintl M et al (2014) A large ApoE ε4/ε4 homozygous cohort reveals no association with Parkinson’s disease. Acta Neurol Belg 114:25–31. doi:10.1007/s13760-013-0223-5 PubMed

115.

Berciano J, Ferrer I (2005) Glial cell cytoplasmic inclusions in SCA2 do not express alpha-synuclein. J Neurol 252:742–744. doi:10.1007/s00415-005-0747-6 PubMed

116.

Factor SA, Qian J, Lava NS et al (2005) False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy. Ann Neurol 57:462–463. doi:10.1002/ana.20389 PubMed

117.

Kamm C, Healy DG, Quinn NP et al (2005) The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain J Neurol 128:1855–1860. doi:10.1093/brain/awh535

118.

Naka H, Ohshita T, Murata Y et al (2002) Characteristic MRI findings in multiple system atrophy: comparison of the three subtypes. Neuroradiology 44:204–209PubMed

119.

Hagerman PJ, Greco CM, Hagerman RJ (2003) A cerebellar tremor/ataxia syndrome among fragile X premutation carriers. Cytogenet Genome Res 100:206–212 72856PubMed

120.

Garland EM, Vnencak-Jones CL, Biaggioni I et al (2004) Fragile X gene premutation in multiple system atrophy. J Neurol Sci 227:115–118. doi:10.1016/j.jns.2004.08.013 PubMed

121.

Yabe I, Soma H, Takei A et al (2004) No association between FMR1 premutations and multiple system atrophy. J Neurol 251:1411–1412. doi:10.1007/s00415-004-0546-5 PubMed

122.

Manolio TA, Collins FS, Cox NJ et al (2009) Finding the missing heritability of complex diseases. Nature 461:747–753. doi:10.1038/nature08494 PubMedCentralPubMed

123.

Sasaki H, Emi M, Iijima H et al (2011) Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy. Mol Brain 4:24. doi:10.1186/1756-6606-4-24 PubMedCentralPubMed

124.

Ferguson MC, Garland EM, Hedges L et al (2014) SHC2 gene copy number in multiple system atrophy (MSA). Clin Auton Res Off J Clin Auton Res Soc 24:25–30. doi:10.1007/s10286-013-0216-8

125.

Sharp AJ, Locke DP, McGrath SD et al (2005) Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 77:78–88. doi:10.1086/431652 PubMedCentralPubMed

126.

Henrichsen CN, Vinckenbosch N, Zöllner S et al (2009) Segmental copy number variation shapes tissue transcriptomes. Nat Genet 41:424–429. doi:10.1038/ng.345 PubMed

127.

Bruder CEG, Piotrowski A, Gijsbers AACJ et al (2008) Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 82:763–771. doi:10.1016/j.ajhg.2007.12.011 PubMedCentralPubMed

128.

Stefanova N, Reindl M, Neumann M et al (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord Off J Mov Disord Soc 22:2196–2203. doi:10.1002/mds.21671

129.

Block ML, Hong J-S (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35:1127–1132. doi:10.1042/BST0351127 PubMed

130.

Brand A, Bauer NG, Hallott A et al (2010) Membrane lipid modification by polyunsaturated fatty acids sensitizes oligodendroglial OLN-93 cells against oxidative stress and promotes up-regulation of heme oxygenase-1 (HSP32). J Neurochem 113:465–476. doi:10.1111/j.1471-4159.2010.06611.x PubMed

131.

Stefanova N, Georgievska B, Eriksson H et al (2012) Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 21:393–404. doi:10.1007/s12640-011-9294-3 PubMed

132.

Bukhatwa S, Zeng B-Y, Rose S, Jenner P (2010) A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Brain Res 1326:174–183. doi:10.1016/j.brainres.2010.02.045 PubMed

133.

Schwarz L, Goldbaum O, Bergmann M et al (2012) Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes. J Mol Neurosci MN 47:256–266. doi:10.1007/s12031-012-9733-5

134.

Korolchuk VI, Menzies FM, Rubinsztein DC (2010) Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584:1393–1398. doi:10.1016/j.febslet.2009.12.047 PubMed

135.

Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z et al (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci Off J Soc Neurosci 31:14508–14520. doi:10.1523/JNEUROSCI.1560-11.2011

136.

Rubinsztein DC, DiFiglia M, Heintz N et al (2005) Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1:11–22PubMed

137.

Stefanova N, Kaufmann WA, Humpel C et al (2012) Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol (Berl) 124:51–65. doi:10.1007/s00401-012-0977-5

138.

Wong MB, Goodwin J, Norazit A et al (2013) SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases. Neurotox Res 23:1–21. doi:10.1007/s12640-012-9358-z PubMed

139.

Höglinger GU, Melhem NM, Dickson DW et al (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699–705. doi:10.1038/ng.859 PubMedCentralPubMed

140.

Welter D, Macarthur J, Morales J et al (2014) The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42:D1001–D1006. doi:10.1093/nar/gkt1229 PubMedCentralPubMed

141.

Keller MF, Saad M, Bras J et al (2012) Using genome-wide complex trait analysis to quantify “missing heritability” in Parkinson’s disease. Hum Mol Genet 21:4996–5009. doi:10.1093/hmg/dds335 PubMedCentralPubMed

142.

Lupski JR, Gonzaga-Jauregui C, Yang Y et al (2013) Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy. Genome Med 5:57. doi:10.1186/gm461 PubMedCentralPubMed

143.

Lieber DS, Vafai SB, Horton LC et al (2012) Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease. BMC Med Genet 13:3. doi:10.1186/1471-2350-13-3 PubMedCentralPubMed

144.

Ionita-Laza I, Makarov V, Yoon S et al (2011) Finding disease variants in Mendelian disorders by using sequence data: methods and applications. Am J Hum Genet 89:701–712. doi:10.1016/j.ajhg.2011.11.003 PubMedCentralPubMed

145.

Gonzaga-Jauregui C, Lupski JR, Gibbs RA (2012) Human genome sequencing in health and disease. Annu Rev Med 63:35–61. doi:10.1146/annurev-med-051010-162644 PubMedCentralPubMed

146.

Guerreiro R, Wojtas A, Bras J et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127. doi:10.1056/NEJMoa1211851 PubMedCentralPubMed

147.

Schork NJ, Murray SS, Frazer KA, Topol EJ (2009) Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 19:212–219. doi:10.1016/j.gde.2009.04.010 PubMedCentralPubMed

148.

Koboldt DC, Steinberg KM, Larson DE et al (2013) The next-generation sequencing revolution and its impact on genomics. Cell 155:27–38. doi:10.1016/j.cell.2013.09.006 PubMedCentralPubMed

149.

Green RC, Berg JS, Grody WW et al (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med Off J Am Coll Med Genet 15:565–574. doi:10.1038/gim.2013.73

150.

Van El CG, Cornel MC, Borry P et al (2013) Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet EJHG 21:580–584. doi:10.1038/ejhg.2013.46

Titel: Multiple system atrophy: the application of genetics in understanding etiology
verfasst von: Monica Federoff
Lucia V. Schottlaender
Henry Houlden
Andrew Singleton
Publikationsdatum: 01.02.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Autonomic Research / Ausgabe 1/2015
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-014-0267-5

Neu in den Fachgebieten Neurologie und Psychiatrie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study

Novel therapeutic approaches in multiple system atrophy

Multiple system atrophy: Using clinical pharmacology to reveal pathophysiology

Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy

Animal models of multiple system atrophy

A short clinical history of multiple system atrophy

Neu in den Fachgebieten Neurologie und Psychiatrie

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung